Alder BioPharmaceuticals licenses clazakizumab rights to Vitaeris
Alder BioPharmaceuticals announced it has licensed the exclusive worldwide rights to clazakizumab to Vitaeris. In exchange, Alder has received an equity stake in Vancouver, BC, based Vitaeris and is eligible to receive royalties and certain other payments. Financial terms were not disclosed. May 06, 2016